Anti CD22 chimeric antigen receptor T cell therapy (Shanghai Yake Biotechnology) |
|
Phase 2 Clinical |
Yake Biotechnology, Beijing Boren Hospital, The First Affiliated Hospital Of Zhejiang University School Of Medicine |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
BAY-1862864 |
BAY-1862864 |
Phase 1 Clinical |
Bayer Ag |
Lymphoma, Non-Hodgkin |
Details
|
Epratuzumab |
AMG-412; CDP-3194; IMMU-103; IMMU-1903; IMMU-hLL2 |
Phase 3 Clinical |
Immunomedics Inc |
Lymphoma, B-Cell; Sjogren's Syndrome; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
CD22 CAR-T Cell Therapy (Hebei Senlang Biotechnology) |
|
Phase 1 Clinical |
Hebei Senlang Biological Technology Co Ltd |
Sarcoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms |
Details
|
CD22-targeted CAR-T cell therapy (PersonGen Biomedicine) |
|
Phase 1 Clinical |
Persongen Biotherapeutics |
Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Neoplasms, Plasma Cell |
Details
|
Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) |
|
Phase 2 Clinical |
People'S Liberation Army General Hospital Military Service |
Leukemia; Lymphoma |
Details
|
Anti-CD22/CD19 monoclonal antibody-toxin conjugate |
|
Phase 1 Clinical |
Ut Southwestern Medical Center |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
UCART-22 |
UCART-22 |
Phase 1 Clinical |
Cellectis |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) |
|
Phase 2 Clinical |
The University Of Texas M.D. Anderson Cancer Center |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) |
|
Phase 1 Clinical |
Seattle Children'S Hospital |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology) |
|
Phase 1 Clinical |
Hrain Biotechnology |
Leukemia, Lymphoid |
Details
|
GTB-1550 |
DT-2219; OXS-1550; DT-2219ARL; IND-100780 |
Phase 2 Clinical |
University Of Minnesota |
Leukemia; Lymphoma, B-Cell |
Details
|
Anti-CD22 CAR-T cell therapy (iCarTAB BioMed) |
|
Phase 2 Clinical |
Icar Bio, China |
Lymphoma, B-Cell |
Details
|
Anti-CD22 CAR T cell therapy (Shanghai GeneChem) |
|
Phase 1 Clinical |
Shanghai Genechem Co Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
CD22-CART |
|
Phase 1 Clinical |
Hrain Biotechnology Co Ltd |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell |
Details
|
TRPH-222 |
CD22-4AP; TRPH-222; CAT-02-106 |
Phase 1 Clinical |
Catalent Inc |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
Anti-CD19/CD22 bispecific CAR-T cell therapy (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine) |
|
Phase 1 Clinical |
The Second Affiliated Hospital Of Henan University Of Traditional Chinese Medicine |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) |
4SCAR-T |
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Neoplasms |
Details
|
Anti-CD22 CAR T cell therapy (Wuhan Bio-Raid) |
|
Phase 1 Clinical |
Wuhan Bio-Raid Biotechnology |
Lymphoma, B-Cell; Multiple Myeloma |
Details
|
AUTO-3 |
AUTO-3 |
Phase 2 Clinical |
University College London |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Dual specificity CD19 and CD20 or CD22 CAR-T cell (Chinese PLA General Hospital) |
|
Phase 2 Clinical |
Pla General Hospital |
Leukemia; Lymphoma, B-Cell |
Details
|
Anti-CD22-CAR T cell therapy (Kecellitics Biotech) |
|
Phase 2 Clinical |
Kecellitics Biotech Company Ltd |
Leukemia; Lymphoma |
Details
|
RD-102 |
RD-102 |
Phase 1 Clinical |
Nanjing Iaso Biotherapeutics Co Ltd |
Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse |
Details
|
Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) |
|
Phase 1 Clinical |
Stanford University |
Lymphoma, B-Cell |
Details
|
JCAR-018 |
JCAR-018 |
Phase 1 Clinical |
National Cancer Institute, Opus Bio |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) |
|
Phase 1 Clinical |
Zhejiang University |
Hematologic Neoplasms |
Details
|
CART22-cells |
CART22-cells |
Phase 1 Clinical |
Novartis Pharma Ag, University Of Pennsylvania |
Leukemia; Lymphoma, B-Cell |
Details
|
Pinatuzumab vedotin |
RO-5541072; ACD22-VCMMAE; RO-5541072-000; RG-7593; FCU-2703; DCDT-2980S |
Phase 2 Clinical |
Genentech Inc |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) |
|
Phase 1 Clinical |
Shanghai Jiaotong University |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19/CD22 chimeric antigen receptor T cell therapy (Nanjing Legend Biotech) |
LCAR-L10D |
Phase 1 Clinical |
Nanjing Legend Biotechnology Co Ltd, Second Affiliated Hospital Xi'An Jiaotong University |
Lymphoma, Large B-Cell, Diffuse |
Details
|
Anti-CD22 CAR-T cell therapy (No. 307 Hospital) |
|
Phase 2 Clinical |
The Fifth Medical Center Of Chinese Pla General Hospital |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
SM-03 |
SM-03; SM-06 |
Phase 3 Clinical |
Lonn Ryonn Pharma Ltd, Sinomab Bioscience Ltd |
Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin |
Details
|
CD19/CD20 Dual CAR-T Cell Therapy (China Immunotech) |
|
Phase 1 Clinical |
China Immunotech Co Ltd |
Lymphoma, Non-Hodgkin |
Details
|
CD19-CD22 CAR-T cells (Shanghai Ultra-T Immune Therapeutics) |
|
Phase 1 Clinical |
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CD19/CD22 dual-target CAR-T cell therapy (Shenzhen University General Hospital) |
|
Phase 2 Clinical |
Shenzhen University General Hospital |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|